IDEAYA Biosciences carries a 52% analyst-implied upside and favorable near-term price momentum, but the underlying business quality is well below the minimum threshold — with free cash flow burning at 25% of revenue, a Piotroski score of 2 out of 9, and a pipeline concentrated in a single lead asset — making this a high-variance speculative setup where quality concerns outweigh the return potential for most investors.
Thesis pillars
- Single Asset Pipeline Concentration↓Deteriorating
- Quality Below Minimum Floor↓Deteriorating
- Cash Burning No Profitability→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 17, 2026· older than 90 days
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $32.36: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 3.24; Below-average business quality.
IDEAYA Biosciences develops targeted cancer therapies (small molecule inhibitors and ADCs) for molecularly defined solid tumors, with nine clinical-stage candidates and no approved products. Lead asset darovasertib is in a Phase 2/3 trial for uveal melanoma; Servier paid $210... Read more
Sell if holding. Engine safety override at $32.36: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 3.24; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 102d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About IDEAYA Biosciences, Inc.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences holds a nine-candidate clinical pipeline anchored by darovasertib, a PKC inhibitor in a registration-enabling Phase 2/3 trial (OptimUM-02) in first-line metastatic uveal melanoma, with 437 patients enrolled by December 2025. The FDA granted darovasertib Breakthrough Therapy designation for neoadjuvant primary uveal melanoma in March 2025. In August 2025, Servier paid $210 million upfront for ex-U.S. commercialization rights, with up to $320 million in potential milestones and mid-teen to low-twenties royalties.
IDEAYA generates revenue from collaboration and license payments rather than product sales — the Servier upfront dominated 2025 cash inflows — with net losses of $113.7 million for 2025 and an accumulated deficit of $736.5 million at year-end. The pipeline spans four focus areas: darovasertib in combination with Pfizer's crizotinib for uveal melanoma; ADC/DDR inhibitor combinations (IDE849 partnered with Hengrui Pharma, IDE034, IDE161); MTAP pathway inhibitors including IDE397 in combination with Gilead's Trodelvy; and next-generation therapies IDE574 and IDE275. GSK notified the company in December 2025 of its intent to terminate two collaboration agreements covering IDE705 and IDE275, effective March 9, 2026. Manufacturing is outsourced to third-party contract manufacturers; the company held $1.05 billion in cash and marketable securities at December 31, 2025.
Show full overview
IDEAYA's near-term regulatory path is disproportionately tied to a single readout. The 10-K discloses that topline progression-free survival data from OptimUM-02 were expected in the first quarter of 2026, and that this data "may enable an accelerated approval filing in the United States." The company has never submitted an NDA; if OptimUM-02 fails to meet its primary endpoint or the FDA requires additional studies, the only remaining approval path depends on overall survival data from the same 437 enrolled patients — a multi-year delay that could weigh on the company's ability to sustain its clinical programs without further dilutive financing.
See also: Healthcare · Biotechnology
From IDEAYA Biosciences, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — IDEAYA Biosciences, Inc.
Latest news
- NEWS RBC Capital Markets Lowers Price Target on IDEAYA Biosciences to $45 — fiscal.ai Nov 4, 2026 negative
- NEWS RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45 — benzinga Nov 4, 2026 positive
- NEWS Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57 — benzinga Nov 4, 2026 neutral
- NEWS Guggenheim Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $52 — benzinga Nov 4, 2026 negative
- NEWS Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $63 — benzinga Nov 4, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:54:12Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinedarovasertib10-K Item 1: 'Darovasertib is an oral, potent and selective small molecule inhibitor of protein kinase C (PKC) and our most advanced clinical program.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $32.36: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Elevated put/call ratio: 3.24; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $30.15. Score 5.2/10, moderate confidence.
Analyst target: $44.84 (+38.6% upside). Prior stop was $30.15. Stop-loss: $30.15.
Concentration risk — Pipeline: darovasertib; Quality below floor (2.0 < 4.0).
IDEAYA Biosciences, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts rate IDYA, with a consensus score of 4.3/5. 13 analysts publish price targets averaging $52.
What does IDEAYA Biosciences, Inc. do?IDEAYA Biosciences develops targeted cancer therapies (small molecule inhibitors and ADCs) for molecularly defined...
IDEAYA Biosciences develops targeted cancer therapies (small molecule inhibitors and ADCs) for molecularly defined solid tumors, with nine clinical-stage candidates and no approved products. Lead asset darovasertib is in a Phase 2/3 trial for uveal melanoma; Servier paid $210 million upfront in August 2025 for ex-U.S. rights, with up to $320 million in milestones.